Evaluation Only. Created with Aspose.PDF. Copyright 2002-2025 Aspose Pty Ltd.

SONIC HEDGEHOG MEDULLOBLASTOMA PANEL DG-5.1.0 (8 GENES)

Gene	Twist X2 covered 10x	Twist X2 covered 20x	srWGS covered 10x	srWGS covered 15x	srWGS covered 20x	Associated Phenotype description and OMIM disease ID
BRCA2	100%	100%	100%	100%	99.8%	Fanconi anemia, complementation group D1, 605724;{Glioblastoma 3}, 613029;{Medulloblastoma}, 155255;{Prostate cancer}, 176807;{Breast-ovarian cancer, familial, 2}, 612555;{Breast cancer, male, susceptibility to}, 114480;{Pancreatic cancer 2}, 613347;Wilms tumor, 194070
ELP1	100%	100%	100%	100%	99.8%	{Medulloblastoma}, 155255;Dysautonomia, familial, 223900
GPR161	100%	100%	100%	100%	99.5%	{Medulloblastoma predisposition syndrome}, 155255
PALB2	100%	100%	100%	100%	99.7%	{Breast-ovarian cancer, familial, susceptibility to, 5}, 620442;{Pancreatic cancer, susceptibility to, 3}, 613348;Fanconi anemia, complementation group N, 610832
PTCH1	100%	100%	100%	100%	99.2%	Basal cell nevus syndrome 1, 109400;Basal cell carcinoma, somatic, 605462;Holoprosencephaly 7, 610828

Evaluation Only. Created with Aspose.PDF. Copyright 2002-2025 Aspose Pty Ltd.

SMARCB1	95.2%	95.2%	100%	100%	99.7%	Rhabdoid tumors, somatic, 609322;{Schwannomatosis-1, susceptibility to}, 162091;Coffin-Siris syndrome 3, 614608;{Rhabdoid tumor predisposition syndrome 1}, 609322
SUFU	100%	100%	100%	100%	99.6%	{Meningioma, familial, susceptibility to}, 607174;Joubert syndrome 32, 617757;Basal cell nevus syndrome 2, 620343;{Medulloblastoma}, 155255
TP53	95.1%	95.1%	100%	99.9%	99.4%	{Basal cell carcinoma 7}, 614740;{Adrenocortical carcinoma, pediatric}, 202300;Hepatocellular carcinoma, somatic, 114550;Breast cancer, somatic, 114480;Li-Fraumeni syndrome, 151623;Pancreatic cancer, somatic, 260350;Nasopharyngeal carcinoma, somatic, 607107;{Osteosarcoma}, 259500;{Choroid plexus papilloma}, 260500;{Colorectal cancer}, 114500;{Glioma susceptibility 1}, 137800;Bone marrow failure syndrome 5, 618165

Gene symbols used follow HGCN guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.
TWIST X2 covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.
srWGS covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.
srWGS covered 15x describes the percentage of a gene's coding sequence that is covered at least 15x when analyzed by WGS mapped against GRCh38.
srWGS covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.
non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.
OMIM release used for OMIM disease identifiers and descriptions : November 25th, 2024.

Evaluation Only. Created with Aspose.PDF. Copyright 2002-2025 Aspose Pty Ltd.

This list is accurate for panel version DG 5.0.0

Ad 1. Blank field signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors